Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Review Article
,
Targeted Therapies
,
Screening
Biomarker-Driven Targeted Therapies in Solid Tumor Malignancies
Hanjie Mo, PharmD, BCOP
,
Catherine Renna, PharmD, BCOP
Hanjie Mo, PharmD, BCOP; Catherine Renna, PharmD, BCOP
Read More
Review Article
,
Adverse Events
,
Antibiotics
,
Drug Resistance
Overcoming Resistance: Antibiotic Guidance for Multidrug-Resistant Febrile Neutropenia in Patients with Cancer
Sonya K. Kedzior, PharmD
,
YoungYoon Ham, PharmD
,
Joseph Bubalo, PharmD, BCPS, BCOP
Sonya K. Kedzior, PharmD; YoungYoon Ham, PharmD; Joseph Bubalo, PharmD, BCOP, BCPS
Read More
FDA Updates
,
Skin Cancer
Libtayo Receives 2 New Indications: For Basal-Cell Carcinoma and for NSCLC
Read More
From the Literature
,
Breast Cancer
,
Dose Escalation/Reduction
Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
From the Literature
,
Bladder Cancer
Enfortumab Vedotin Superior to Chemotherapy in Urothelial Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
From the Literature
,
Leukemia
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
Read More
FDA Updates
,
Lung Cancer
Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC
Read More
FDA Updates
,
Leukemia
,
Pediatric Cancer
Vyxeos Now Indicated for Pediatric Patients with AML
Read More
FDA Updates
,
Lymphoma
Ukoniq, New Targeted Therapy, FDA Approved for Marginal-Zone and Follicular Lymphoma
Read More
FDA Updates
,
Lymphoma
FDA Approved Breyanzi, Novel CAR T-Cell Therapy, for Large B-Cell Lymphoma
Read More
87
88
89
90
91
92
93
Page 90 of 197
Results 891 - 900 of 1963